We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma

This study has suspended participant recruitment.
(Revisions due - Enroll to cohort 2)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01269424
First Posted: January 4, 2011
Last Update Posted: December 22, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Stanton Gerson MD, Case Comprehensive Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)